Brought to you by 
Sarepta sells priority review voucher to Gilead for $125mm
21 Sep 2020
Executive Summary
Sarepta Therapeutics Inc. sold its rare pediatric disease priority review voucher (PRV) to Gilead Sciences Inc. for $125mm. Sarepta was granted the PRV when Exondys51 was approved by the FDA for patients with Duchenne muscular dystrophy amenable to exon skipping, and will now use the cash from the sale to support development of additional exon skipping candidates and enhancement of the company's antisense platform.
Deal Industry
- Biotechnology
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Financing
- Priority Review Voucher (PRV) Sale
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Sarepta sells priority review voucher to Gilead for $125mm
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice